Investigational drug · Phase 3
XZP-3287
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Breast Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Jul 17, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "XZP-3287"
First trial start
2021
Nov 16, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "XZP-3287", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "XZP-3287" as an intervention, largest first.
Sihuan Pharmaceutical Holdings Group Ltd.Industry
NCT04539496 · 402 participants · Start May 22, 2018 · Primary completion Jul 31, 2023
Drug: XZP-3287; XZP-3287;Letrozole;Anastrozole;Fulvestrant and 1 more · For: Metastasis Solid Tumors; Advanced Breast Cancer
Sites: Beijing, China
- A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast CancerPivotal-lookingActive, not recruiting
Xuanzhu Biopharmaceutical Co., Ltd.Industry
NCT05257395 · 397 participants · Start Mar 14, 2022 · Primary completion Dec 5, 2025
Drug: XZP-3287+ Letrozole/Anastrozole; Placebo + Letrozole/Anastrozole · For: Advanced Breast Cancer
Sites: Harbin, China
- A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast CancerPivotal-lookingActive, not recruiting
Xuanzhu Biopharmaceutical Co., Ltd.Industry
NCT05077449 · 300 participants (planned) · Start Nov 16, 2021 · Primary completion Feb 22, 2024
Drug: XZP-3287+Fulvestrant; Placebo + Fulvestrant · For: Advanced Breast Cancer
Sites: Beijing, China
- Effect of Clarithromycin and Rifampicin on the Pharmacokinetics of XZP-3287 in Healthy SubjectsStatus unknown
Xuanzhu Biopharmaceutical Co., Ltd.Industry
NCT04951713 · 60 participants (planned) · Start Jul 2021 · Primary completion Sep 2021
Drug: XZP-3287 combined with clarithromycin; XZP-3287 combined with rifampicin · For: Healthy
Sites: Bengbu, China
Xuanzhu Biopharmaceutical Co., Ltd.Industry
NCT04951765 · 24 participants (planned) · Start Aug 2021 · Primary completion Aug 2021
Drug: XZP-3287; XZP-3287 and 4 more · For: Healthy
Sites: Qingdao, China
- A Clinical Trial of XZP-3287 for Material BalanceStatus unknown
Xuanzhu Biopharmaceutical Co., Ltd.Industry
NCT05478109 · 10 participants (planned) · Start Aug 2, 2022 · Primary completion Jan 4, 2023
Drug: [14C]XZP-3287 · For: Healthy Male Subjects
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Development and validation of an LC-MS/MS method for simultaneous determination of XZP-3287(bireociclib) and its metabolites in human plasma, and its clinical pharmacokinetics application.
Liang B, Li Y, Xu L, et al. · J Chromatogr B Analyt Technol Biomed Life Sci 2025
- An open-label, single-arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR-positive, HER2-negative advanced breast cancer patients: BRIGHT-1 trial.
Wang J, Zhang Q, Sun T, et al. · Cancer Commun (Lond) 2025
Also in development for Advanced Breast Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- UtidelonePhase 38 trials
Beijing Biostar Pharmaceuticals Co., Ltd. · Ovarian Cancer, HER2-negative Breast Cancer Patients With Brain Metastases, Gastric or Gastroesophageal Junction Adenocarcinoma
- KN026PlacboPhase 37 trials
Shanghai JMT-Bio Inc. · HER2-positive Gastric Cancer, Advanced Breast Cancer, Resectable HER2-positive Breast Cancer
- PalazestrantOP-1250Phase 32 trials
Olema Oncology, Inc. · Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
- RYZ101Phase 32 trials
RayzeBio, Inc. · Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer
- ZovegalisibPhase 31 trial
Relay Therapeutics, Inc. · PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor
- MHB039APhase 24 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Malignant Solid Tumor, Advanced Breast Cancer, Advanced Lung Cancer
- AK146D1Phase 23 trials
Akeso · Advanced Non Small Cell Lung Cancer (NSCLC), Advanced Breast Cancer, Urothelial Carcinoma (UC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.